Regulation of Serum Sodium Levels during Chemotherapy Using Selective Arginine Vasopressin V2-Receptor Antagonist Tolvaptan in a Four-Year-Old Girl with a Suprasellar Germ Cell Tumor
Abstract
1. Introduction
2. Case Presentation
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Berl, T. Vasopressin antagonists. N. Engl. J. Med. 2015, 372, 2207–2216. [Google Scholar] [CrossRef] [PubMed]
- Aditya, S.; Rattan, A. Vaptans: A new option in the management of hyponatremia. Int. J. Appl. Basic Med. Res. 2012, 2, 77–83. [Google Scholar] [CrossRef] [PubMed]
- Cuesta, M.; Thompson, C.J. The syndrome of inappropriate antidiuresis (SIAD). Best. Pract. Res. Clin. Endocrinol. Metab. 2016, 30, 175–187. [Google Scholar] [CrossRef] [PubMed]
- Rondon-Berrios, H. Urea for Chronic Hyponatremia. Blood Purif. 2020, 49, 212–218. [Google Scholar] [CrossRef] [PubMed]
- Arima, H.; Goto, K.; Motozawa, T.; Mouri, M.; Watanabe, R.; Hirano, T.; Ishikawa, S.E. Open-label, multicenter, dose-titration study to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone. Endocr. J. 2021, 68, 17–29. [Google Scholar] [CrossRef] [PubMed]
- Willemsen, R.H.; Delgado-Carballar, V.; Elleri, D.; Thankamony, A.; Burke, G.A.; Nicholson, J.C.; Dunger, D.B. Tolvaptan use during hyperhydration in paediatric intracranial lymphoma with SIADH. Endocrinol. Diabetes Metab. Case Rep. 2016, 2016, 2016. [Google Scholar] [CrossRef] [PubMed]
- Tuli, G.; Tessaris, D.; Einaudi, S.; De Sanctis, L.; Matarazzo, P. Tolvaptan Treatment in Children with Chronic Hyponatremia due to Inappropriate Antidiuretic Hormone Secretion: A Report of Three Cases. J. Clin. Res. Pediatr. Endocrinol. 2017, 9, 288–292. [Google Scholar] [CrossRef] [PubMed]
- Gürbüz, F.; Taştan, M.; Turan, İ.; Yüksel, B. Efficiency of Single Dose of Tolvaptan Treatment During the Triphasic Episode After Surgery for Craniopharyngioma. J. Clin. Res. Pediatr. Endocrinol. 2019, 11, 202–206. [Google Scholar] [CrossRef] [PubMed]
- Marx-Berger, D.; Milford, D.V.; Bandhakavi, M.; Van’t Hoff, W.; Kleta, R.; Dattani, M.; Bockenhauer, D. Tolvaptan is successful in treating inappropriate antidiuretic hormone secretion in infants. Acta Paediatr. 2016, 105, 334–337. [Google Scholar] [CrossRef] [PubMed]
- Koksoy, A.Y.; Kurtul, M.; Ozsahin, A.K.; Cayci, F.S.; Tayfun, M.; Bayrakci, U.S. Tolvaptan Use to Treat SIADH in a Child. J. Pediatr. Pharmacol. Ther. 2018, 23, 494–498. [Google Scholar] [CrossRef] [PubMed]
- Kraayvanger, L.; Latza, J.; Vockelmann, C.; Berlit, P.; Weber, R. Tolvaptan treatment of severe stroke-like symptoms and bilateral subcortical diffusion restriction due to syndrome of inappropriate secretion of ADH after polytrauma. J. Neurol. 2014, 261, 1436–1438. [Google Scholar] [CrossRef] [PubMed]
- Verbalis, J.G.; Goldsmith, S.R.; Greenberg, A.; Korzelius, C.; Schrier, R.W.; Sterns, R.H.; Thompson, C.J. Diagnosis, evaluation, and treatment of hyponatremia: Expert panel recommendations. Am. J. Med. 2013, 126, S1–S42. [Google Scholar] [CrossRef] [PubMed]
Blood Chemistry | Endocrine Tests | (Reference Values) | ||||
---|---|---|---|---|---|---|
TP | 6.5 | g/dL | ADH | 1.1 | pg/mL | <0.5 |
BUN | 8.0 | mg/dL | BNP | <5.8 | pg/mL | <18.4 |
UA | 3.9 | mg/dL | Aldosterone | 6.0 | ng/mL | 3.6–24.0 |
Cre | 0.19 | mg/dL | PRA | 1.0 | ng/mL/h | 0.2–2.7 |
Na | 121 | mEq/L | ACTH | 8.9 | pg/mL | 7.2–21.0 |
K | 3.6 | mEq/L | Cortisol | 5.5 | μg/dL | 6.4–21.0 |
Cl | 93 | mEq/L | ||||
TG | 198 | mg/dL | ||||
BG | 106 | mg/dL | ||||
Plasma Osm | 252 | mOsm/kg | ||||
Urinalysis | ||||||
Urine specific gravity | 1.024 | |||||
Na | 194 | mEq/L | ||||
Cre | 48 | mEq/L | ||||
Urine Osm | 708 | mOsm/kg |
Authors | Age (Years) | Cause of SIADH | Initial Dose of Tolvaptan (mg/kg/dose) | Change in s-Na (mEq/L) * | Maximum UV (mL/kg/h) * | References |
---|---|---|---|---|---|---|
Koksoy, et al. | 16 | Idiopathic | 0.28 | 115 to 122 in 16 h | 9 | [10] |
Marx-Berger, et al. | 0.2 | Idiopathic | 0.8 | 138 to 153 in 2 days | No data | [9] |
Marx-Berger, et al. | 0.3 | Idiopathic | 0.6 | No data | No data | [9] |
Willemsen, et al. | 11 | Intracranial B-cell lymphoma | 0.14 | 119 to 130 in 2 days | 8 | [6] |
Tuli, et al. | 7 | ROHHAD syndrome | 0.06 | No data | No data | [7] |
Tuli, et al. | 4 | A large sellar and suprasellar tumor | 0.1 | No data | No data | [7] |
Tuli, et al. | 5 | Hypothalamic astrocytoma | 0.05 | No data | No data | [7] |
Gürbüz, et al. | 13 | Craniopharyngioma | 0.13 | 117 to 126 in 4 h | 8.1 | [8] |
Kraayvanger, et al. | 17 | Severe polytrauma | 15 mg/day | 116 to 139 in 24 h | No data | [11] |
Hiroshima, et al. | 4 | Suprasellar germ cell tumor | 0.2 | 126 to 138 mEq/L in 10 h | 15 at 4 h | This study |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hiroshima, S.; Nyuzuki, H.; Sasaki, S.; Ogawa, Y.; Nagasaki, K. Regulation of Serum Sodium Levels during Chemotherapy Using Selective Arginine Vasopressin V2-Receptor Antagonist Tolvaptan in a Four-Year-Old Girl with a Suprasellar Germ Cell Tumor. Children 2021, 8, 293. https://doi.org/10.3390/children8040293
Hiroshima S, Nyuzuki H, Sasaki S, Ogawa Y, Nagasaki K. Regulation of Serum Sodium Levels during Chemotherapy Using Selective Arginine Vasopressin V2-Receptor Antagonist Tolvaptan in a Four-Year-Old Girl with a Suprasellar Germ Cell Tumor. Children. 2021; 8(4):293. https://doi.org/10.3390/children8040293
Chicago/Turabian StyleHiroshima, Shota, Hiromi Nyuzuki, Sunao Sasaki, Yohei Ogawa, and Keisuke Nagasaki. 2021. "Regulation of Serum Sodium Levels during Chemotherapy Using Selective Arginine Vasopressin V2-Receptor Antagonist Tolvaptan in a Four-Year-Old Girl with a Suprasellar Germ Cell Tumor" Children 8, no. 4: 293. https://doi.org/10.3390/children8040293
APA StyleHiroshima, S., Nyuzuki, H., Sasaki, S., Ogawa, Y., & Nagasaki, K. (2021). Regulation of Serum Sodium Levels during Chemotherapy Using Selective Arginine Vasopressin V2-Receptor Antagonist Tolvaptan in a Four-Year-Old Girl with a Suprasellar Germ Cell Tumor. Children, 8(4), 293. https://doi.org/10.3390/children8040293